Alternative scenario: the upside breakout of 0.459 would call for 0.509 and 0.539.
My pivot point is at 0.459.
My preference: the downside prevails as long as 0.459 is resistance.
Comment:
The RSI is below its neutrality area at 50.
The MACD is negative and below its signal line.
The configuration is negative.
Moreover, the share stands below its 20 and...
Text me if you have any questions/comments for me.
-----
IMU
- Previous analysis was done on 4 Oct (red arrow) – suggested waiting for a successful rebound around 47.5 cents before plotting entry
- Since then, the stock has created a new high, retraced, and looks to be rebounding off the short-term support
- If have taken the entry suggestion, you should be...
Text me if you have any questions/comments for me.
-----
IMU
- First time doing a written analysis on IMU
- Stock is currently trading at previous strong resistance (created in 2007)
- A good rebound from here would form a strong support at current levels
- A successful rebound looks to be at 0.475 levels
- R is borderline 10%
- Strategy-to-buy (DYOR) – Suggest...
Imugene (ASX:IMU) is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors.
3 Scenarios identified
Bullish:
- MACD still Bullish
- Volume increasing
- RSI still trending Bullish although currently Overbought
- Bullish bounce off .382 Fib...
Not my cup of tea but since I put it on twitter for those who are interested here it is markings & all.
Technically it has formed an inverted H&S pattern and has broken out of the neckline ($0.039c) Bullish, targeting $0.06c & may see a pullback to test the break of the neckline. Speculative so please DYOR. It is an idea I came across whilst scanning my charts
$IMU (ASX)- daily, price is holding onto 70.70 fibs and making higher lows..coiling imo...indis are also showing bullish signs...might see a movement soon imo..Let's see
FA wise: waiting on the cancer vaccine trial results
Disc: I hold...
Will be interesting to see if IMU gets more of a bump during and after its conference today. MASSIVE buy side demand with 220 buyers for 107,568,372 units vs 61 sellers for 26,085,482 units.
Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2...
Love this stock fundamentally but in my opinion, it has had a great short-term run and needs a pullback for the next leg up. Should see it retrace to these support levels and then continue upwards towards 5c short term. I will be selling a portion to rebuy at a lower price.
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
ASX
